Ozempic and Wegovy maker Novo Nordisk now worth $500B amid soaring popularityNew York Post • 01/31/24
Novo Nordisk Stock Hits Record High as Wegovy Maker Sees Up To 26% Sales Growth This YearInvestopedia • 01/31/24
Novo Nordisk's Wegovy Comes In Light, But Ozempic Puts Up A Commanding BeatInvestors Business Daily • 01/31/24
Novo Nordisk results: profits grow by over 30% off the back of weight-loss brand WeGovyInvezz • 01/31/24
Norway's giant wealth fund touts possibility of Novo Nordisk, Eli Lilly joining the trillion-dollar clubCNBC • 01/31/24
Weight-Loss Drug Boom Sends Novo Nordisk Profits Soaring. Why the Success Brings Challenges.Barrons • 01/31/24
Novo Nordisk's sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion in 2023GlobeNewsWire • 01/31/24
Wall Street Analysts See Novo Nordisk (NVO) as a Buy: Should You Invest?Zacks Investment Research • 01/30/24